PP
MED icon

Paladin Partners’s Medifast MED Stock Holding History

Paladin Partners’s Portfolio MED Stock Details MED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-30
Closed -$318 – 213
2026
Q2 		$318 Hold
30
– – ﹤0.01% 207
2026
Q1 		$306 Hold
30
– – ﹤0.01% 205
2025
Q4 		$320 Buy
+30
New +$359 ﹤0.01% 208

Other funds holding MED

GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MAFA
MJT & Associates Financial Advisory Monteviceo, Minnesota $155M AUM 15.7% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Paladin Partners's MED Position: Q3 2026 in Review

Paladin Partners sold out of Medifast (MED) in Q3 2026, closing a stake of 30 shares — an estimated $318 sold.

Paladin Partners first reported a position in MED in Q4 2025 and held it in 3 quarters. The position peaked at $320 in Q4 2025. 4 funds tracked by Wall St. Rank hold MED as of Q3 2026.

  • Paladin Partners reported no remaining Medifast position as of Q3 2026 after selling out during the quarter.
  • Paladin Partners sold 30 Medifast shares in Q3 2026, an estimated $318.
  • Paladin Partners first reported a position in Medifast in Q4 2025 and held it in 3 quarters.
  • Paladin Partners's Medifast position peaked at $320 in Q4 2025.
  • 4 funds tracked by Wall St. Rank held Medifast as of Q3 2026.

Based on Paladin Partners's 13F filing for Q3 2026, filed 6 Oct 2026.